TherapeuticsMD (TXMD) Cost of Revenue (2011 - 2023)

TherapeuticsMD (TXMD) has reported Cost of Revenue for 13 consecutive years, with $106000.0 the latest figure, recorded in Q3 2023.

• For the quarter ending Q3 2023, Cost of Revenue fell 70.06% year-over-year to $106000.0; the trailing twelve-month figure through Dec 2023 stood at $106000.0 (down 92.41% YoY), and the FY2022 full-year result was $1.4 million, changed 0.36% from the prior year.
• Cost of Revenue declined to $106000.0 in Q3 2023 per TXMD's latest filing, from $354000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.6 million in Q4 2020 and bottomed at -$12.7 million in Q4 2021.
• Historically, Cost of Revenue has averaged $1.6 million across 5 years, with a median of $2.1 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Cost of Revenue jumped 255.91% in 2020, then slumped 327.54% in 2021.
• Over 5 years, Cost of Revenue stood at $2.9 million in 2019, then surged by 93.85% to $5.6 million in 2020, then plunged by 327.54% to -$12.7 million in 2021, then jumped by 102.79% to $354000.0 in 2022, then slumped by 70.06% to $106000.0 in 2023.
• According to Business Quant data, Cost of Revenue over the past three periods registered $106000.0, $354000.0, and $348000.0 for Q3 2023, Q3 2022, and Q2 2022 respectively.